Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial
المؤلفون المشاركون
Pourazizi, Mohsen
Fazel, Farhad
Nikpour, Hossein
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-01-17
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Purpose.
To evaluate the efficacy of three intravitreal bevacizumab (IVB) injections versus the same combined with 2% of topical dorzolamide in the treatment of diabetic macular edema (DME).
Methods.
In this randomized double-masked clinical trial, 32 eyes of 16 treatment-naive patients with bilateral DME were enrolled.
The eyes were randomly assigned to receive three monthly injections of IVB (1.25 mg) plus topical dorzolamide 2% twice daily or IVB (1.25 mg) plus topical artificial tear twice daily.
Best-corrected visual acuity (BCVA) was the primary outcome of the study followed by the central macular thickness (CMT) and central macular volume (CMV) as the secondary outcomes.
Results.
Mean BCVA changes were insignificant in both groups.
It changed from 0.21 ± 0.08 logMAR at baseline to 0.23 ± 0.09 (P=0.24) in the combination group and from 0.18 ± 0.09 logMAR to 0.21 ± 0.09 (P=0.11) in the IVB alone group, at 3 months, respectively.
Changes in mean CMT and CMV were significant in both groups.
However, the difference between the groups was not significant at all the visits.
In the study, no major ocular complication or systemic side effects were noted regarding IVB or topical dorzolamide.
Conclusion.
This randomized contralateral clinical trial demonstrated that adjuvant topical dorzolamide with IVB injection had no additional effects on IVB in the treatment of DME over a three-month course.
This trial is registered with the Iranian Registry of Clinical Trials under the registration code IRCT20131229015975N5.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Fazel, Farhad& Nikpour, Hossein& Pourazizi, Mohsen. 2020. Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial. BioMed Research International،Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1136206
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Fazel, Farhad…[et al.]. Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial. BioMed Research International No. 2020 (2020), pp.1-5.
https://search.emarefa.net/detail/BIM-1136206
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Fazel, Farhad& Nikpour, Hossein& Pourazizi, Mohsen. Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1136206
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1136206
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر